Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
552 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 35.45 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 20.79 | Oscillator | Neutral |
| Williams %R (14) | -86.42 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.12 (Hist 0.01) | Oscillator | Buy |
| Average Directional Index (14) | 20.57 (+DI 15.5 / -DI 24.0) | Trend | Sell |
Current price $0.4752
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 18, 26 | HC Wainwright & Co. |
| EMA 20 | 0.65 | MA | Strong Sell |
| SMA 20 | 0.65 | MA | Strong Sell |
| EMA 50 | 0.90 | MA | Strong Sell |
| SMA 50 | 0.97 | MA | Strong Sell |
| SMA 200 | 2.29 | MA | Strong Sell |
| maintain |
| Buy |
| Buy |
| May 18, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 22, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 13, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Nov 19, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 23, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 18, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 14, 26 | Schmitt Daniel M | director, officer: President, CEO and Director | M-Exempt | 272,056 | — |
| Aug 14, 26 | Schmitt Daniel M | director, officer: President, CEO and Director | F-InKind | 120,521 @ $1.01 | $121.7K |
| Aug 14, 26 | Schmitt Daniel M | director, officer: President, CEO and Director | M-Exempt | 272,056 | — |
| May 21, 26 | Zabrowski Dan | director | A-Award | 15,000 @ $2.42 | $36.30K |
| May 21, 26 | Thomson Todd S | director, 10 percent owner: | A-Award | 15,000 @ $2.42 | $36.30K |
| May 21, 26 | Sawhney Roger | director | A-Award | 15,000 @ $2.42 | $36.30K |
| May 21, 26 | Ronneberg Amy L | director | A-Award | 15,000 @ $2.42 | $36.30K |
| May 21, 26 | Keyes Jason A | director | A-Award | 15,000 @ $2.42 | $36.30K |
TTM vs. 5-year historical average (annual ratios)
| Metric | ACTU | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.5x | -5.0x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.7x | EPS est. -0.73 | Elevated |
| Price / Book | 11.5x | 378.7x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -0.4x | 527.4x | Discount |
| Return on equity | -346.2% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.41 | 0.02 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -55.57 | Distress |
Discounted cash flow model
Stock news · updated daily
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, today announced that it will present at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14-16, 2026, in New York City. In addition, the management team will be available for one-on-one meetings during the conference.
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing novel therapies for high-impact, difficult-to-treat cancers, today announced new preclinical data evaluating elraglusib in combination with zoldonrasib (RMC-9805), an investigational RAS(ON) G12D-selective inhibitor, and daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, in pancreatic ductal adenocarcinoma (PDAC), including models resistant to FOLFIRINOX chemotherapy. The studies were conducted in collaboration with investigators at Northwestern University and the Mayo Clinic.
Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -0.20 | -0.20 | Beat 1.6% | — |
| May 14, 2026 | -0.23 | -0.24 | Miss -4.3% | — |
| Mar 26, 2026 | -0.24 | -0.18 | Beat 25.0% | — |
| Nov 13, 2025 | -0.27 | -0.25 | Beat 7.4% | — |
| Aug 14, 2025 | -0.19 | -0.30 | Miss -57.9% | — |
| May 15, 2025 | -0.30 | -0.32 | Miss -6.7% | — |
| 4 | Aug 14, 2026 | 2026-08-14 17:00:03 | View |
| 10-Q | Aug 14, 2026 | 2026-08-14 16:05:42 | View |
| 8-K | Jul 17, 2026 | 2026-07-17 16:30:34 | View |
| 8-K | May 22, 2026 | 2026-05-22 16:43:53 | View |
| 4 | May 22, 2026 | 2026-05-22 16:15:21 | View |
| 4 | May 22, 2026 | 2026-05-22 16:14:24 | View |
Proxy statement (DEF 14A) disclosures